|International Clinical Psychopharmacology
continues to maintain its high standing in publishing research and clinical
practice within the field. This respected journal largely focuses on psychotropic
drugs, covering phase I-IV studies, clinical studies, side effects and
epidemiology. With regular volume indexes to assist further research and
investigation, this journal is an invaluable reference source.
International Clinical Psychopharmacology attracts ever increasing interests from the pharmaceutical industry. Much of the latest research within psychopharmacology is published in the form of supplements to the journal, and these undergo the same rigorous peer review as those in the regular issues. Supplements form part of the annual subscription, though they are also available separately.
Throughout its eleven year history, International Clinical Psychopharmacology has provided an essential link between research and clinical practice throughout psychopharmacology. Its fundamental aim is to enhance our understanding of psychotropic drugs in health and disease. To achieve this, the journal publishes the results of early phase I and II studies, as well those of controlled clinical trials of psychotropic drugs in phase III and IV.
Research papers published in the journal are of the highest quality, and, as such, influence clinical practice worldwide.
Supplements, which are included with the subscription, form an important part of the journal. Recent supplements reflect the ever-increasing interest that the journal has attracted. These have included reviews of antidepressants and antipsychotics and proceedings of important international meetings including recent ECNP and BAP conferences.
All papers submitted are strictly peer reviewed. There are no submission or page charges for papers submitted to this journal.